BIONTECH SE-ADR (BNTX)
US09075V1026 - ADR
Taking everything into account, BNTX scores 4 out of 10 in our fundamental rating. BNTX was compared to 572 industry peers in the Biotechnology industry. BNTX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BNTX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BNTX has reported negative net income.
In the past year BNTX had a positive cash flow from operations.
BNTX had positive earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: BNTX reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of -2.08%, BNTX belongs to the top of the industry, outperforming 91.15% of the companies in the same industry.
The Return On Equity of BNTX (-2.44%) is better than 92.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.08% | ||
| ROE | -2.44% | ||
| ROIC | N/A |
ROA(3y)36.53%
ROA(5y)17.56%
ROE(3y)46.06%
ROE(5y)20.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of BNTX has grown nicely.
Looking at the Gross Margin, with a value of 87.71%, BNTX belongs to the top of the industry, outperforming 90.97% of the companies in the same industry.
BNTX's Gross Margin has been stable in the last couple of years.
BNTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y98.55%
PM growth 5YN/A
GM growth 3Y-1.33%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
BNTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BNTX has been reduced compared to 1 year ago.
BNTX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BNTX has a worse debt to assets ratio.
2.2 Solvency
BNTX has an Altman-Z score of 6.96. This indicates that BNTX is financially healthy and has little risk of bankruptcy at the moment.
BNTX has a Altman-Z score of 6.96. This is amongst the best in the industry. BNTX outperforms 83.54% of its industry peers.
The Debt to FCF ratio of BNTX is 0.25, which is an excellent value as it means it would take BNTX, only 0.25 years of fcf income to pay off all of its debts.
BNTX has a Debt to FCF ratio of 0.25. This is amongst the best in the industry. BNTX outperforms 97.17% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that BNTX is not too dependend on debt financing.
BNTX has a Debt to Equity ratio (0.01) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.25 | ||
| Altman-Z | 6.96 |
ROIC/WACCN/A
WACC6.91%
2.3 Liquidity
BNTX has a Current Ratio of 7.33. This indicates that BNTX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.33, BNTX is doing good in the industry, outperforming 69.38% of the companies in the same industry.
A Quick Ratio of 7.21 indicates that BNTX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.21, BNTX is doing good in the industry, outperforming 68.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.33 | ||
| Quick Ratio | 7.21 |
3. Growth
3.1 Past
BNTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -117.52%.
The Earnings Per Share has been growing by 279.64% on average over the past years. This is a very strong growth
Looking at the last year, BNTX shows a very negative growth in Revenue. The Revenue has decreased by -54.07% in the last year.
BNTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 97.22% yearly.
EPS 1Y (TTM)-117.52%
EPS 3Y279.64%
EPS 5YN/A
EPS Q2Q%20.9%
Revenue 1Y (TTM)-54.07%
Revenue growth 3Y99.36%
Revenue growth 5Y97.22%
Sales Q2Q%39.04%
3.2 Future
The Earnings Per Share is expected to decrease by -35.65% on average over the next years. This is quite bad
BNTX is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -2.27% yearly.
EPS Next Y-181.62%
EPS Next 2Y-70.3%
EPS Next 3Y-41.67%
EPS Next 5Y-35.65%
Revenue Next Year-38.48%
Revenue Next 2Y-22.7%
Revenue Next 3Y-15.87%
Revenue Next 5Y-2.27%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BNTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
BNTX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BNTX is cheaper than 95.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.72 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BNTX's earnings are expected to decrease with -41.67% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-70.3%
EPS Next 3Y-41.67%
5. Dividend
5.1 Amount
BNTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIONTECH SE-ADR
NASDAQ:BNTX (1/13/2025, 8:05:21 PM)
After market: 113.74 0 (0%)113.74
-9.11 (-7.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners19.03%
Inst Owner Change-0.05%
Ins Owners2.05%
Ins Owner ChangeN/A
Market Cap27.41B
Analysts77.78
Price Target139.52 (22.67%)
Short Float %2.53%
Short Ratio2.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)44.04%
Min EPS beat(2)-62.82%
Max EPS beat(2)150.91%
EPS beat(4)1
Avg EPS beat(4)11.69%
Min EPS beat(4)-62.82%
Max EPS beat(4)150.91%
EPS beat(8)5
Avg EPS beat(8)271.9%
EPS beat(12)8
Avg EPS beat(12)194.11%
EPS beat(16)12
Avg EPS beat(16)219.92%
Revenue beat(2)1
Avg Revenue beat(2)47.3%
Min Revenue beat(2)-13.02%
Max Revenue beat(2)107.62%
Revenue beat(4)1
Avg Revenue beat(4)4.24%
Min Revenue beat(4)-56.98%
Max Revenue beat(4)107.62%
Revenue beat(8)2
Avg Revenue beat(8)-8.54%
Revenue beat(12)5
Avg Revenue beat(12)4.91%
Revenue beat(16)9
Avg Revenue beat(16)15.52%
PT rev (1m)0.09%
PT rev (3m)9.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-77.92%
EPS NY rev (1m)1.59%
EPS NY rev (3m)-27.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-39.14%
Revenue NY rev (1m)1.24%
Revenue NY rev (3m)-1.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 8.84 | ||
| P/FCF | 27.72 | ||
| P/OCF | 17.67 | ||
| P/B | 1.41 | ||
| P/tB | 1.5 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2
EYN/A
EPS(NY)-3.52
Fwd EYN/A
FCF(TTM)4.1
FCFY3.61%
OCF(TTM)6.44
OCFY5.66%
SpS12.86
BVpS80.89
TBVpS75.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.08% | ||
| ROE | -2.44% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.71% | ||
| FCFM | 31.9% |
ROA(3y)36.53%
ROA(5y)17.56%
ROE(3y)46.06%
ROE(5y)20.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)61.51%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y98.55%
PM growth 5YN/A
GM growth 3Y-1.33%
GM growth 5Y-1.09%
F-Score2
Asset Turnover0.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.25 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 261.47% | ||
| Cap/Sales | 18.15% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.33 | ||
| Quick Ratio | 7.21 | ||
| Altman-Z | 6.96 |
F-Score2
WACC6.91%
ROIC/WACCN/A
Cap/Depr(3y)295.05%
Cap/Depr(5y)262.38%
Cap/Sales(3y)7.13%
Cap/Sales(5y)20.83%
Profit Quality(3y)216.26%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-117.52%
EPS 3Y279.64%
EPS 5YN/A
EPS Q2Q%20.9%
EPS Next Y-181.62%
EPS Next 2Y-70.3%
EPS Next 3Y-41.67%
EPS Next 5Y-35.65%
Revenue 1Y (TTM)-54.07%
Revenue growth 3Y99.36%
Revenue growth 5Y97.22%
Sales Q2Q%39.04%
Revenue Next Year-38.48%
Revenue Next 2Y-22.7%
Revenue Next 3Y-15.87%
Revenue Next 5Y-2.27%
EBIT growth 1Y-120.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-206.11%
EBIT Next 3Y-45.75%
EBIT Next 5Y-6.9%
FCF growth 1Y-92.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-87.88%
OCF growth 3YN/A
OCF growth 5YN/A